Publications by authors named "Yu-Chen Barrett"

Claim this Profile
E
Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study.
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian'an Wang, Yu Chen Barrett

Cardiol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Charles Frost, Samira Garonzik, Andrew Shenker, Yu Chen Barrett, Frank LaCreta

Clin Pharmacol Drug Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Pulmonary Function and Asthma Symptoms.
Patrick W Sullivan, Vahram H Ghushchyan, Jessica Marvel, Yu Chen Barrett, Anne L Fuhlbrigge

J Allergy Clin Immunol Pract· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma.
Robert J Yetman, Yu Chen Barrett, Zhaoqing Wang, Robert Adamczyk, Jessie Wang

Thromb Haemost· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.
Todd G Kirchgessner, Paul Sleph, Jacek Ostrowski, John Lupisella, Carol S Ryan, Yu Chen Barrett

Cell Metab· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Charles E Frost, Yan Song, Andrew Shenker, Jessie Wang, Yu Chen Barrett

Clin Pharmacokinet· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.
Charles Frost, Yan Song, Yu Chen Barrett, Jessie Wang, Janice Pursley

Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
Charles Frost, Andrew Shenker, Mohit D Gandhi, Janice Pursley, Yu Chen Barrett

Br J Clin Pharmacol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Vijay V Upreti, Jessie Wang, Yu Chen Barrett, Wonkyung Byon, Rebecca A Boyd

Br J Clin Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects.
Yimin Cui, Yan Song, Jessie Wang, Zhigang Yu, Alan Schuster, Yu Chen Barrett

Clin Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Charles Frost, Sunil Nepal, Jessie Wang, Alan Schuster, Wonkyung Byon, Yu Chen Barrett

Br J Clin Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors.
Yu Chen Barrett, Zhaoqing Wang, Robert M Knabb

Clin Appl Thromb Hemost· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Charles Frost, Jessie Wang, Sunil Nepal, Alan Schuster, Yu Chen Barrett

Br J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Yu Chen Barrett, Jessie Wang, Yan Song, Janice Pursley, Philip Wastall

Thromb Haemost· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Yu Chen Barrett, Jessie Wang, Robert Knabb, Puneet Mohan

Thromb Haemost· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Yu Chen Barrett, Zhaoqing Wang, Charles Frost, Andrew Shenker

Thromb Haemost· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
Gopi Shankar, Viswanath Devanarayan, Lakshmi Amaravadi, Yu Chen Barrett, Ronald Bowsher

J Pharm Biomed Anal· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Feng Roger Luo, Yu Chen Barrett, Zheng Yang, Amy Camuso, Kelly McGlinchey

Cancer Chemother Pharmacol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
Eugen Koren, Holly W Smith, Elizabeth Shores, Gopi Shankar, Deborah Finco-Kent, Yu-Chen Barrett

J Immunol Methods· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.
Yu Chen Barrett, William Ebling, Henry Pieniaszek, Jeffrey Billheimer, Dietmar Seiffert

J Pharm Biomed Anal· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fit-for-purpose method development and validation for successful biomarker measurement.
Jean W Lee, Viswanath Devanarayan, Yu Chen Barrett, Russell Weiner, John Allinson

Pharm Res· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated on-line SPE LC-MS/MS method to quantitate 6beta-hydroxycortisol and cortisol in human urine: use of the 6beta-hydroxycortisol to cortisol ratio as an indicator of CYP3A4 activity.
Yu Chen Barrett, Billy Akinsanya, Shu-Ying Chang, Ole Vesterqvist

J Chromatogr B Analyt Technol Biomed Life Sci· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
Anthony R Mire-Sluis, Yu Chen Barrett, Viswanath Devanarayan, Eugene Koren, Hank Liu

J Immunol Methods· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.
Dietmar Seiffert, Andrew M Stern, William Ebling, Richard J Rossi, Yu Chen Barrett

Blood· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.
Henry J Pieniaszek, Anna F Davidson, Harry L Walton, Donald J Pinto, Richard E Olson, Yu Chen Barrett

J Pharm Biomed Anal· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis